GenMont Biotech Inc (3164) - Net Assets
Based on the latest financial reports, GenMont Biotech Inc (3164) has net assets worth NT$1.39 Billion TWD (≈ $43.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.58 Billion ≈ $49.75 Million USD) and total liabilities (NT$185.54 Million ≈ $5.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of GenMont Biotech Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.39 Billion |
| % of Total Assets | 88.25% |
| Annual Growth Rate | 8.86% |
| 5-Year Change | -0.15% |
| 10-Year Change | -1.38% |
| Growth Volatility | 23.37 |
GenMont Biotech Inc - Net Assets Trend (2003–2024)
This chart illustrates how GenMont Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is GenMont Biotech Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for GenMont Biotech Inc (2003–2024)
The table below shows the annual net assets of GenMont Biotech Inc from 2003 to 2024. For live valuation and market cap data, see GenMont Biotech Inc (3164) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.48 Billion ≈ $46.62 Million |
+2.11% |
| 2023-12-31 | NT$1.45 Billion ≈ $45.66 Million |
-3.21% |
| 2022-12-31 | NT$1.50 Billion ≈ $47.17 Million |
-1.78% |
| 2021-12-31 | NT$1.52 Billion ≈ $48.03 Million |
+2.87% |
| 2020-12-31 | NT$1.48 Billion ≈ $46.69 Million |
+2.33% |
| 2019-12-31 | NT$1.45 Billion ≈ $45.62 Million |
-7.33% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.23 Million |
+14.00% |
| 2017-12-31 | NT$1.37 Billion ≈ $43.19 Million |
+7.12% |
| 2016-12-31 | NT$1.28 Billion ≈ $40.32 Million |
-14.71% |
| 2015-12-31 | NT$1.50 Billion ≈ $47.27 Million |
-6.07% |
| 2014-12-31 | NT$1.60 Billion ≈ $50.32 Million |
+90.77% |
| 2013-12-31 | NT$837.28 Million ≈ $26.38 Million |
-2.82% |
| 2012-12-31 | NT$861.62 Million ≈ $27.15 Million |
-4.77% |
| 2011-12-31 | NT$904.75 Million ≈ $28.50 Million |
+22.62% |
| 2010-12-31 | NT$737.87 Million ≈ $23.25 Million |
+16.08% |
| 2009-12-31 | NT$635.68 Million ≈ $20.03 Million |
+4.28% |
| 2008-12-31 | NT$609.60 Million ≈ $19.21 Million |
+16.19% |
| 2007-12-31 | NT$524.64 Million ≈ $16.53 Million |
+13.62% |
| 2006-12-31 | NT$461.75 Million ≈ $14.55 Million |
+59.15% |
| 2005-12-31 | NT$290.14 Million ≈ $9.14 Million |
-1.37% |
| 2004-12-31 | NT$294.16 Million ≈ $9.27 Million |
+18.31% |
| 2003-12-31 | NT$248.64 Million ≈ $7.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GenMont Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12801700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$128.02 Million | 9.47% |
| Common Stock | NT$865.11 Million | 64.00% |
| Other Comprehensive Income | NT$18.38 Million | 1.36% |
| Other Components | NT$340.27 Million | 25.17% |
| Total Equity | NT$1.35 Billion | 100.00% |
GenMont Biotech Inc Competitors by Market Cap
The table below lists competitors of GenMont Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IT City Public Company Limited
BK:IT
|
$47.97 Million |
|
Findi Ltd
AU:FND
|
$47.97 Million |
|
SRG HOUSING FINANCE ORD (BSE)
NSE:SRGHFL
|
$48.00 Million |
|
Korea Refract
KO:010040
|
$48.01 Million |
|
Energia Latina SA
SN:ENLASA
|
$47.96 Million |
|
NOMADAR Corp. Class A Common Stock
NASDAQ:NOMA
|
$47.95 Million |
|
IBKS No. 15 Special Purpose Acquisition Co. Ltd.
KQ:373200
|
$47.93 Million |
|
Ewein Bhd
KLSE:7249
|
$47.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenMont Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,316,307,000 to 1,351,779,000, a change of 35,472,000 (2.7%).
- Net income of 57,251,000 contributed positively to equity growth.
- Dividend payments of 43,256,000 reduced retained earnings.
- Other comprehensive income increased equity by 34,254,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$57.25 Million | +4.24% |
| Dividends Paid | NT$43.26 Million | -3.2% |
| Other Comprehensive Income | NT$34.25 Million | +2.53% |
| Other Changes | NT$-12.78 Million | -0.95% |
| Total Change | NT$- | 2.69% |
Book Value vs Market Value Analysis
This analysis compares GenMont Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.04x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | NT$8.67 | NT$17.70 | x |
| 2005-12-31 | NT$8.42 | NT$17.70 | x |
| 2006-12-31 | NT$10.35 | NT$17.70 | x |
| 2007-12-31 | NT$10.12 | NT$17.70 | x |
| 2008-12-31 | NT$11.25 | NT$17.70 | x |
| 2009-12-31 | NT$11.40 | NT$17.70 | x |
| 2010-12-31 | NT$13.32 | NT$17.70 | x |
| 2011-12-31 | NT$12.71 | NT$17.70 | x |
| 2012-12-31 | NT$15.72 | NT$17.70 | x |
| 2013-12-31 | NT$13.75 | NT$17.70 | x |
| 2014-12-31 | NT$24.07 | NT$17.70 | x |
| 2015-12-31 | NT$16.87 | NT$17.70 | x |
| 2016-12-31 | NT$14.39 | NT$17.70 | x |
| 2017-12-31 | NT$15.03 | NT$17.70 | x |
| 2018-12-31 | NT$16.68 | NT$17.70 | x |
| 2019-12-31 | NT$15.52 | NT$17.70 | x |
| 2020-12-31 | NT$15.10 | NT$17.70 | x |
| 2021-12-31 | NT$15.87 | NT$17.70 | x |
| 2022-12-31 | NT$15.59 | NT$17.70 | x |
| 2023-12-31 | NT$15.21 | NT$17.70 | x |
| 2024-12-31 | NT$15.59 | NT$17.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenMont Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.86%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.26x
- Recent ROE (4.24%) is above the historical average (2.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -13.50% | -35.54% | 0.31x | 1.21x | NT$-59.82 Million |
| 2005 | -3.33% | -7.25% | 0.36x | 1.27x | NT$-32.93 Million |
| 2006 | 2.45% | 6.36% | 0.33x | 1.17x | NT$-33.49 Million |
| 2007 | 11.42% | 22.68% | 0.44x | 1.14x | NT$7.13 Million |
| 2008 | 8.82% | 17.18% | 0.44x | 1.17x | NT$-6.87 Million |
| 2009 | 14.20% | 24.44% | 0.49x | 1.19x | NT$25.48 Million |
| 2010 | 20.87% | 28.67% | 0.38x | 1.93x | NT$76.85 Million |
| 2011 | 5.65% | 13.33% | 0.19x | 2.21x | NT$-29.37 Million |
| 2012 | 3.30% | 12.53% | 0.16x | 1.66x | NT$-57.73 Million |
| 2013 | 3.69% | 10.00% | 0.22x | 1.64x | NT$-52.84 Million |
| 2014 | -24.18% | -68.40% | 0.32x | 1.09x | NT$-545.89 Million |
| 2015 | -6.53% | -18.33% | 0.33x | 1.09x | NT$-248.07 Million |
| 2016 | -18.44% | -43.63% | 0.39x | 1.10x | NT$-363.90 Million |
| 2017 | 3.41% | 11.98% | 0.25x | 1.12x | NT$-88.12 Million |
| 2018 | 10.60% | 38.87% | 0.25x | 1.11x | NT$8.95 Million |
| 2019 | 4.15% | 16.59% | 0.22x | 1.13x | NT$-81.05 Million |
| 2020 | 4.58% | 18.72% | 0.20x | 1.21x | NT$-72.04 Million |
| 2021 | 8.22% | 26.44% | 0.25x | 1.23x | NT$-24.51 Million |
| 2022 | 4.22% | 15.46% | 0.22x | 1.25x | NT$-78.15 Million |
| 2023 | 2.51% | 10.37% | 0.19x | 1.26x | NT$-98.64 Million |
| 2024 | 4.24% | 14.86% | 0.23x | 1.26x | NT$-77.93 Million |
Industry Comparison
This section compares GenMont Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,948,507,556
- Average return on equity (ROE) among peers: 3.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenMont Biotech Inc (3164) | NT$1.39 Billion | -13.50% | 0.13x | $47.96 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan. It offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. The company was founded in 2000 and is based in Tainan City, Taiwan.